Cargando…

Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota

Impairments in liver function lead to different complications. As chronic liver disease progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to changes in gut microbiota and, therefore, in the host–microbiome interaction, leading to a proinflammatory state. Alterations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendez-Sanchez, Nahum, Coronel-Castillo, Carlos Esteban, Cordova-Gallardo, Jacqueline, Qi, Xingshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603944/
https://www.ncbi.nlm.nih.gov/pubmed/37887176
http://dx.doi.org/10.3390/antibiotics12101475
_version_ 1785126717340254208
author Mendez-Sanchez, Nahum
Coronel-Castillo, Carlos Esteban
Cordova-Gallardo, Jacqueline
Qi, Xingshun
author_facet Mendez-Sanchez, Nahum
Coronel-Castillo, Carlos Esteban
Cordova-Gallardo, Jacqueline
Qi, Xingshun
author_sort Mendez-Sanchez, Nahum
collection PubMed
description Impairments in liver function lead to different complications. As chronic liver disease progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to changes in gut microbiota and, therefore, in the host–microbiome interaction, leading to a proinflammatory state. Alterations in gut microbiota composition and permeability, known as gut dysbiosis, have important implications in CLD; alterations in the gut–liver axis are a consequence of liver disease, but also a cause of CLD. Furthermore, gut dysbiosis plays an important role in the progression of liver cirrhosis and decompensation, particularly with complications such as hepatic encephalopathy and spontaneous bacterial peritonitis. In relation to this, antibiotics play an important role in treating CLD. While certain antibiotics have specific indications, others have been subjected to continued study to determine whether or not they have a modulatory effect on gut microbiota. In contrast, the rational use of antibiotics is important, not only because of their disrupting effects on gut microbiota, but also in the context of multidrug-resistant organisms. The aim of this review is to illustrate the role of gut microbiota alterations in CLD, the use and impact of antibiotics in liver cirrhosis, and their harmful and beneficial effects.
format Online
Article
Text
id pubmed-10603944
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106039442023-10-28 Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota Mendez-Sanchez, Nahum Coronel-Castillo, Carlos Esteban Cordova-Gallardo, Jacqueline Qi, Xingshun Antibiotics (Basel) Review Impairments in liver function lead to different complications. As chronic liver disease progresses (CLD), hypoalbuminemia and alterations in bile acid compositions lead to changes in gut microbiota and, therefore, in the host–microbiome interaction, leading to a proinflammatory state. Alterations in gut microbiota composition and permeability, known as gut dysbiosis, have important implications in CLD; alterations in the gut–liver axis are a consequence of liver disease, but also a cause of CLD. Furthermore, gut dysbiosis plays an important role in the progression of liver cirrhosis and decompensation, particularly with complications such as hepatic encephalopathy and spontaneous bacterial peritonitis. In relation to this, antibiotics play an important role in treating CLD. While certain antibiotics have specific indications, others have been subjected to continued study to determine whether or not they have a modulatory effect on gut microbiota. In contrast, the rational use of antibiotics is important, not only because of their disrupting effects on gut microbiota, but also in the context of multidrug-resistant organisms. The aim of this review is to illustrate the role of gut microbiota alterations in CLD, the use and impact of antibiotics in liver cirrhosis, and their harmful and beneficial effects. MDPI 2023-09-22 /pmc/articles/PMC10603944/ /pubmed/37887176 http://dx.doi.org/10.3390/antibiotics12101475 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mendez-Sanchez, Nahum
Coronel-Castillo, Carlos Esteban
Cordova-Gallardo, Jacqueline
Qi, Xingshun
Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
title Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
title_full Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
title_fullStr Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
title_full_unstemmed Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
title_short Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota
title_sort antibiotics in chronic liver disease and their effects on gut microbiota
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603944/
https://www.ncbi.nlm.nih.gov/pubmed/37887176
http://dx.doi.org/10.3390/antibiotics12101475
work_keys_str_mv AT mendezsancheznahum antibioticsinchronicliverdiseaseandtheireffectsongutmicrobiota
AT coronelcastillocarlosesteban antibioticsinchronicliverdiseaseandtheireffectsongutmicrobiota
AT cordovagallardojacqueline antibioticsinchronicliverdiseaseandtheireffectsongutmicrobiota
AT qixingshun antibioticsinchronicliverdiseaseandtheireffectsongutmicrobiota